* Enfusion Inc is expected to show a rise in quarterly revenue when it reports results on November 4 for the period ending September 30 2024

* The Chicago Illinois-based company is expected to report a 17.5% increase in revenue to $52.166 million from $44.4 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

* ​LSEG's mean analyst estimate for Enfusion Inc is for earnings of 6 cents per share.

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy," 3 "hold" and 3 "sell" or "strong sell."

* The mean earnings estimate of analysts was unchanged in the last three months. ​

* Wall Street's median 12-month price target for Enfusion Inc is $9.57​, above​ its last closing price of $8.91. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI

ENDING ARTESTIMAT ESTIMATE MET, SE %

E® MISSED

Jun. 30 2024 0.06 0.06 0.05 Missed -11.1

Jan. 1 2024 0.03 0.04 0.06 Beat 65.5

Dec. 31 2023 0.05 0.04 Missed -23.8​

Sep. 30 2023 0.04 0.05 0.04 Missed -12.5

​​Jan. 0.04 0.04 0.04 Met -4.1

1 0001

Mar. 31 2023 0.03 0.03 0.02 Missed -27.1​

Dec. 31 2022 0.03 0.03 0.04 Beat 36.4

Jan. 1 0001 0.01 0.02 0.03 Beat 50

This summary was machine generated November 1 at 14:42 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)